What is Tibsovo? | Information & FAQ
Last updated: 14 October 2022
Article reviewed by Dr. Jan de Witt
What is Tibsovo (ivosidenib)?
Tibsovo is an IDH1 inhibitor (targeted therapy) medication indicated to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation.1
It is available in tablet form each containing 250mg of ivosidenib.1
How much does Tibsovo (ivosidenib) cost?
For more information about how much Tibsovo costs and how we can help you access it, please click on the button below
What is Tibsovo (ivosidenib) used for?
Tibsovo is a prescription medicine used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation in:1
- Newly-Diagnosed Acute Myeloid Leukemia
Tibsovo (ivosidenib) is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
- Relapsed or Refractory Acute Myeloid Leukemia
Tibsovo (ivosidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Is Tibsovo (ivosidenib) chemotherapy?
No, Tibsovo is not a chemotherapy, but a targeted therapy. Targeted therapies are designed for specific types of cancer to block the growth and spread of cancer cells. Chemotherapy can kill cancer cells or stop them from dividing.2
How does Tibsovo (ivosidenib) work?
Ivosidenib is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme.
Susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of ivosidenib and/or 2) inhibition of mutant IDH1 enzymatic activity at concentrations of ivosidenib sustainable at the recommended dosage according to validated methods. The most common of such mutations are R132H and R132C substitutions.
Ivosidenib was shown to inhibit selected IDH1 R132 mutants at much lower concentrations than wild-type IDH1 in vitro. Inhibition of the mutant IDH1 enzyme by ivosidenib led to decreased 2- HG levels and induced myeloid differentiation in vitro and in vivo in mouse xenograft models of IDH1-mutated AML. In blood samples from patients with AML with mutated IDH1, ivosidenib decreased 2-HG levels ex-vivo, reduced blast counts, and increased percentages of mature myeloid cells. 2,3